Clarivate (CLVT) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
16 Jan, 2026Executive summary
Q3 2024 revenue declined to $622.2M, down 3.9% year-over-year, with all segments and geographies impacted by lower transactional sales, divestitures, and market headwinds.
Net loss for Q3 was $65.6M, compared to net income of $12.3M in Q3 2023, driven by a $14M goodwill impairment and FX losses.
Adjusted EBITDA for Q3 was $264.4M (42.5% margin), down from $281.4M (43.5%) last year.
CEO transition led to a comprehensive review and launch of a Value Creation Plan focused on recurring revenue, sales execution, product innovation, and portfolio simplification.
All previous guidance for 2024 and long-range outlooks have been withdrawn to prioritize execution of the transformation plan.
Financial highlights
Q3 2024 revenue was $622.2M, down $25M or 3.9% year-over-year, with net loss of $65.6M and basic/diluted EPS of $(0.09).
Adjusted diluted EPS for Q3 was $0.19, down from $0.21 year-over-year.
Operating cash flow for Q3 was $202.9M, up $39.5M year-over-year; free cash flow was $126.3M, up $24.6M, but year-to-date free cash flow is $298.4M, down $76.3M.
Adjusted EBITDA margin for Q3 was 42.5%, down 100 bps year-over-year; net loss margin was (10.5)%.
Cash and cash equivalents at September 30, 2024, were $388.5M, with $691.9M available under the revolving credit facility.
Outlook and guidance
All full-year and long-range guidance has been withdrawn due to leadership transition and strategic review.
Management expects continued pressure on transactional and IP revenues, with subscription growth driven by price increases.
More details and KPIs to track progress will be provided in the next earnings call.
Latest events from Clarivate
- Accelerating recurring revenue and AI-driven innovation while divesting Life Sciences to boost growth.CLVT
Wolfe FinTech Forum10 Mar 2026 - Exceeded guidance, improved recurring revenue, and set 2026 growth targets amid portfolio shift.CLVT
Q4 202524 Feb 2026 - Q2 revenue fell and net loss widened on impairment, but guidance and renewal rates held firm.CLVT
Q2 20242 Feb 2026 - Guidance lowered for organic growth, but AI innovation and buybacks signal a strategic shift.CLVT
Oppenheimer 27th Virtual Annual Technology, Internet & Communications Conference2 Feb 2026 - AI-driven innovation and recurring revenue focus set the stage for accelerated growth and margin gains.CLVT
Stifel 2024 Cross Sector Insight Conference1 Feb 2026 - Targeting 4%-6% organic growth by 2026 through innovation, AI, and recurring revenue.CLVT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Aiming for 4-6% organic growth by 2026, with AI and product innovation as key drivers.CLVT
Goldman Sachs Communacopia + Technology Conference 202420 Jan 2026 - Q1 2025 saw organic growth, margin expansion, and stable free cash flow amid divestitures.CLVT
Q1 202524 Dec 2025 - Shift to subscriptions and disposals aims to boost margins, predictability, and organic growth.CLVT
Q4 202416 Dec 2025